Hepatitis C Infection - Liver
The eighth Round Table Conference on Hepatitis C Infection,
under the aegis of the Ranbaxy Science Foundation held at the India Habitat
Centre on October 15, 2001, was attended by some of the most prominent gastroenterologists,
pathologists and other related medical specialists from across the country.
The conference sought to elucidate the various aspects of the infection and
recent medical advances in the field of management and treatment. The highlights
of the conference are discussed below.
Hepatitis C is an infectious viral disease of the liver that
affects more than 150 million people worldwide. Of these almost 15-20% people
develop chronic liver disease, liver cirrhosis and liver cancer. However, this
condition has not received as much attention as other infectious conditions,
notably AIDS, because of ignorance about the disease and the absence of effective
treatment options. In India, approximately 18 million people are estimated to
be infected.
Causes and transmission of the disease:
The infection is caused by the Hepatitis C Virus (HCV) that
enters the body through two main routes – parenteral (through blood) and
non-parenteral (sexual or vectors). The incubation period of the infection is
2-26 weeks i.e., the symptoms may take this much time to appear after a person
has been infected. It may take as long as 5-10 years for an infected person
to develop chronic liver disease after exposure to the virus.
The transmission of the virus by the parenteral route can occur
through a variety of ways, the most common being through blood transfusion when
the donor blood is infected. Other ways through which the virus may be transmitted
are:
- Intra-venous drug use - through infected syringes used during drug usage.
- Body fluids like saliva/vaginal secretions etc. However, this form of
transmission is very rare and occurs only in rare cases.
- Siblings and children of infected persons may contract the disease through
sharing contaminated instruments like razors, tooth brushes, etc.
- Piercing of the skin as in the case of ear piercing, tattooing etc., with
non-sterilised instruments increases the risk of exposure to the virus.
- Though breast-feeding does not cause transmission of the infection, mothers
who show symptoms of Hepatitis C infection should refrain from breast-feeding
their children. The transmission of the infection is not dependant upon
the type of delivery.
In most non-parenteral cases, a continuous exposure to the
virus over a considerable period of time is needed before the individual becomes
infected. Other alternate modes of transmission are through insect vectors and
human bites.
Risk factors for Hepatitis C Infection:
Anyone who has had an exchange of blood due to any reason is
at a risk for the infection. Since the primary mode of transmission of the HCV
is through blood transfusion, any person who has had a surgery is susceptible
to the infection. Of these, the maximum risk is to those patients who have had
an obstetric/gynaecological surgery, an abdominal surgery or operation of the
eyes or the heart. Dental procedures also expose an individual to the risk of
infection. Patients on haemodialysis or those who have had organ transplants
are also at an increased risk.
Other risk factors, apart from blood transfusion are:
- Health workers who work with trauma patients are at an increased risk.
Studies have shown that wearing gloves by health workers while handling
such patients decreases the risk by 10 times.
- Risk of intrafamilial transmission increases with increased severity of
symptoms of the infected person, increased duration of contact, sexual contact
between family members and the number of infected persons present in the
family.
- Age of a person is also a dependent variable, with the risk of infection
increasing for people more than 45 years of age.
- The type of viral infection (genotype 1, 2 or 3) is also important in
determining the chronicity of the condition.
The rapidity of spread of the infection also depends on conditions
like malignancy, alcohol use, other infections like HIV, lichen planus, vitiligo,
urticaria, arthritis etc. the presence of any other infectious disease increases
the risk of the infection with the HCV. Apart from the liver, the pancreas is
another organ that is affected by the virus.
Symptoms and Diagnosis:
The Hepatitis C Virus (HCV) is also reportedly asymptomatic
in almost 70-90% of the cases making diagnosis very difficult. Experts believe
that if a patient who has had a recent surgery comes with symptoms of liver
malfunction or jaundice, Hepatitis C infection must be suspected and checked
for. Some of the laboratory tests that detect HCV are –
- ELISA
- RIBA (Recombinant Immunoblot Assay)
- HCV-RNA testing
- Matrix
- Liatek III
- DB-2 blot test
- Murex blot test
Treatment modalities:
The main form of treatment of HCV infection is through drugs
like Interferon, Amantadine and Ribavarin. A combination therapy of Interferon
and Ribavarin for 6 months is most commonly used for HCV treatment. However,
there are certain conditions in which therapy should be used with utmost caution.
Some of these conditions are:
- Kidney failure/transplant
- HIV infection
- Children
- Blood disorders
When the patient is already on chemotherapy or any other immunosuppressive
treatment.
Ribavarin is the drug of choice along with Interferon for HCV
treatment, but it is not used in conditions like pregnancy, heart and kidney
problems and psychological illnesses. Some categories of people do not respond
to treatment at all and in such patients alternatives need to be sought. Elderly
and overweight (>95 kg) patients and those with advanced fibrosis do not
respond to this drug therapy. Patients who respond well to medication during
the first week are also more likely to respond later and thus have a better
prognosis.
The current status of HCV vaccine is not too optimistic due
to certain obstacles in the path of development of potent vaccines. There are
too many diverse strains of the Hepatitis C virus to have be responsive to one
vaccine. Even within an individual, the virus changes and evolves thus making
its isolation and treatment difficult. No small animal models are currently
available for vaccine testing.
In light of the above information, control of hepatitis C infection
is an ambiguous proposition. By the middle of this century, HCV will be a major
chronic disease. Treatment of Hepatitis B is already available, so the epidemiology
of Hepatitis C must be understood and given enough importance to prevent it
from taking on epidemic proportions.